STOCK TITAN
  1. Home
  2. Sec-filings
  3. GTBP
  4. [EFFECT] GT Biopharma, Inc. SEC Filing

[EFFECT] GT Biopharma, Inc. SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
EFFECT

Rhea-AI Filing Summary

Analyzing...
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: January 30, 2026 5:00 P.M.
Form: S-1
CIK: 0000109657
Company Name: GT Biopharma, Inc.
File Number: 333-292856

Source: View Original Filing on SEC EDGAR

Stock GTBP logo
Gt Biopharma Inc

NASDAQ:GTBP

GTBP Rankings

#6196 Ranked by Market Cap
N/A Ranked by Dividends

GTBP Latest News

Feb 3, 2026
GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3
Jan 15, 2026
GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers
Nov 19, 2025
GT Biopharma, Inc. (NASDAQ:GTBP) Offers Near-Term Catalyst Opportunity with Advancing Phase 1 Trials
Nov 14, 2025
GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Oct 23, 2025
GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies

GTBP Latest SEC Filings

Jan 30, 2026
[424B3] GT Biopharma, Inc. Prospectus Filed Pursuant to Rule 424(b)(3)
Jan 21, 2026
[S-1] GT Biopharma, Inc. Files IPO Registration Statement
Nov 26, 2025
[8-K] GT Biopharma, Inc. Reports Material Event
Nov 14, 2025
[10-Q] GT Biopharma, Inc. Quarterly Earnings Report
Nov 14, 2025
[8-K] GT Biopharma, Inc. Reports Material Event

GTBP Stock Data

13.23M
9.91M
20.5%
15.16%
5.15%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN FRANCISCO